ClinicalTrials.gg

Program

fazamorexant

Also written as “YZJ-1139”, “YZJ-1139 tablets” and “YZJ-1139 20mg”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders, led by Shanghai Haiyan Pharmaceutical Technology.

Furthest: phase 3, since Aug 24, 20229 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Haiyan Pharmaceutical Technology90 open or runningphase 3since Aug 24, 2022Aug 24, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2022First study: phase 3 study in Sleep Initiation and Maintenance DisordersFirst studyNCT05525637 · 1,037 enrolled · China
  2. Oct 31, 20243 phase 1 studies in Sleep Initiation and Maintenance DisordersNCT06680531, NCT06671470, NCT06671444
  3. Nov 1, 2024Phase 2 study in Sleep Initiation and Maintenance DisordersNCT06680505 · 300 enrolled · China
  4. Nov 1, 20243 phase 1 studies in Sleep Initiation and Maintenance DisordersNCT06673927, NCT06671509, NCT06685341
  5. May 9, 2025Phase 3 study in Sleep Initiation and Maintenance DisordersNCT06975514 · 61 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06975514Sleep Initiation and Maintenance Disorders · China3CompletedJul 21, 202561
NCT06685341Sleep Initiation and Maintenance Disorders · China1CompletedApr 10, 201920
NCT06680505Sleep Initiation and Maintenance Disorders · China2CompletedSep 30, 2020300
NCT06673927Sleep Initiation and Maintenance Disorders · China1CompletedNov 21, 2018104
NCT06671509Sleep Initiation and Maintenance Disorders · China1CompletedApr 18, 202424
NCT06680531Sleep Initiation and Maintenance Disorders · China1CompletedSep 19, 202424
NCT06671470Sleep Initiation and Maintenance Disorders · China1CompletedSep 13, 202427
NCT06671444Sleep Initiation and Maintenance Disorders · China1CompletedOct 11, 202416
NCT05525637Sleep Initiation and Maintenance Disorders · China3CompletedJul 7, 20231,037

How it is read

Names in the registry

  • “YZJ-1139”, 6 entries
  • “YZJ-1139 tablets”, 2 entries
  • “YZJ-1139 20mg”, 2 entries
  • “YZJ-1139 40mg”, 2 entries
  • “YZJ-1139 simulated tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.